Michael French Quoted in 340B Report Article About Views on Trump’s Plan to Move 340B Program
Michael French, an attorney in the Quarles & Brady Health & Life Sciences Practice Group, was quoted in a 340B Report article that discussed initial views and reactions to President Trump’s plan to move the 340B drug pricing program from the Health Resources and Services Administration (HRSA) to the Centers for Medicare and Medicaid Services (CMS). There are mixed reviews with some raising concerns, while others arguing that the move makes sense.
An excerpt:
“This may signal that the administration does not intend to ‘rock the boat,’ at least in the short term, even if 340B oversight ultimately moves under CMS’ purview. Nonetheless, it’s certainly plausible that areas of focus during audits may change per CMS directives to its contracted auditors,” he said in an email.
French added that “although removed from the final proposal, the previous leaked version seemed to signal that CMS ultimately desires to increase oversight over 340Bsavings utilization—thus, it’s possible that CMS would prioritize implementing federal340B covered entity reporting requirements similar to those currently in place in several states.”
Please visit our Federal Policy Watch: Monitoring White House Developments page for more insight about navigating changes at the federal level.